Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer
Critical Reviews in Oncology/Hematology, 04/13/2012Fedele P et al.
The two randomized trials (BOLERO–2 and TAMRAD) evaluating everolimus±endocrine therapy in a selected subgroup of HR–positive metastatic breast cancer patients have demonstrated a significant improvement in progression free survival for the combination compared to the endocrine therapy alone. The data reported so far show that the combination of target agents with endocrine therapy is effective in overcoming acquired resistance in patients with hormone receptor positive metastatic breast cancer.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.